microRNA-126 Is a Tumor Suppressor of Granulosa Cell Tumor Mediated by Its Host Gene EGFL7

Tu, Jiajie; Cheung, Hoi‐Hung; Lü, Gang; Chan, Casey K.; Chen, Zi‐Jiang; Chan, Wai‐Yee

doi:10.3389/fonc.2019.00486

Cited by 9 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some miRNAs play distinct roles in different types of cancers. miR-126 originally recognized as endothelial-specific miRNA plays an essential role in angiogenesis and vascular integrity [25] and has been shown to function as a critical tumor suppressor in various solid tumors [26,27]. In contrast, it has been demonstrated that miR-126 is aberrantly expressed and reported to possess a oncogenic role in core binding factor leukemia [28,29].…”

Section: Discussionmentioning

confidence: 99%

Regulation of miR-126 and miR-122 Expression and Response of Imatinib Treatment on Its Expression in Chronic Myeloid Leukemia Patients

et al. 2021

View full text Add to dashboard Cite

Background: MicroRNAs (miRNAs) have been observed to exhibit altered expression patterns in chronic myeloid leukemia (CML). Therefore, this study was aimed to evaluate the clinical importance of miR-126 and miR-122 expression in concert to imatinib response in CML patients. Methods: The present study included 100 CML and 100 healthy subjects. The expression of the 2 miRNAs was performed using TaqMan probe chemistry, and snU6 was used as internal control. Results: The expression of miR-126 and miR-122 was downregulated in CML patients, with a mean fold change ± SD 0.20 ± 0.33 and 0.22 ± 0.37, respectively. While the expression of both miRNAs was analysed before and after imatinib treatment, it was observed that the expression levels of both were increased after imatinib treatment by 26.25-fold (5.33 against 0.20) and 13.95-fold (3.07 against 0.22) and the increase was statistically significant (p < 0.0001 and p < 0.0001, respectively). The expression of miR-126 was not conclusive when compared in different clinical stages of the CML disease as it showed a decreased expression in patients with accelerated phase compared to chronic phase (mean fold change = 0.03 and 0.27, respectively), but patients with chronic phase and blastic phase had comparable expression (mean fold change = 0.27 and 0.24, respectively). We also observed an increased expression of both miRNAs after imatinib therapy in each clinical phase. Conclusion: The study concludes that expression of miR-126 and miR-122 increases after imatinib treatment in CML patients and that miR-126 defines the good responders of imatinib therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Regulation of miR-126 and miR-122 Expression and Response of Imatinib Treatment on Its Expression in Chronic Myeloid Leukemia Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…MiR-126-3p located in the host gene of epidermal growth factor domain 7 (EGFL7) of human chromosome 9q34.3, was also involved in different rearrangements in various cancers ( 61 ). One of the most notable targets in lung cancer is EGFL7 ( 62 , 63 ). The functions of miR-126-3p ranged from angiogenesis to cell proliferation regulation ( 64 ).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA expression integrated analysis and identification of novel biomarkers in small cell lung cancer: a meta-analysis

Han¹,

Li²,

Li³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background Small cell lung cancer (SCLC) is an aggressive and recalcitrant cancer. In recent years, studies focused on the abnormal expression of microRNA which has proven valuable in terms of prognosis, diagnosis and treatment in SCLC. To address the limitations of independent studies data, a meta-analysis seems necessary for further exploration of microRNA as biological target and regulatory factor in SCLC. Methods We performed comprehensive literature retrieval in GEO database and EBI ArrayExpress database. The microRNA expression data was extracted from 4 related researches (GSE15008, GSE74190, GSE19945, GSE77380), which was obtained from GEO database. In each included study, the R. Affymetrix Expression Console’s Limma package and RMA algorithms were used to screen for raw data for gene chip quality control, standardization, log2 conversion and differential expression of the gene chip, respectively. Significant microRNA meta-signatures were identified by Robust Rank Aggregation method. Subsequently, gene ontology (GO) enrichment analysis and pathway analysis were performed using bioinformatics tools. Results We found a significant microRNA meta-signature of six up-regulated (hsa-miR-182-5p, hsa-miR-96-5p, hsa-miR-7-5p, hsa-miR-301b-3p, hsa-miR-130b-3p, hsa-miR-210-3p) and four down-regulated (hsa-miR-126-3p, hsa-miR-451a, hsa-miR-145-5p, hsa-miR-486-5p) microRNA s in meta-analysis approaches. GO analysis showed that target gene of meta-signatures microRNA was mainly enriched in endosome, chordate embryonic development and transforming growth factor beta receptor. The related functional gene of microRNA meta signature synergistically targeting SCLC signaling pathway was confirmed by enrichment analysis. In particular, neurotrophin and TGF-beta signaling pathway play the most important roles in the pathway network. Conclusions Our study identified 10 highly significant and consistently dysregulated microRNA s from 4 datasets, which offering convincing molecular targets and regulatory factors in future research of SCLC.

show abstract

“…Through miRNA profiling, juvenile- and adult-derived cell-lines have been shown to be biologically distinct, but this still needs to be addressed in vivo. Different studies by Tu et al showed that miR-10a promotes granulosa cell tumor development via the PTEN-AKT/Wnt regulatory axis, while miR-126 is a tumor suppressor of granulosa cell tumor development via the regulation of EGFL7 [ 72 , 73 ].…”

Section: Dysregulation Of Mirnas In Rare Gynecological Cancersmentioning

confidence: 99%

“…miR-9 [ 55 ], miR-10a [ 73 ], miR-21 [ 126 ], miR-590-5p [ 108 ], miR-3147 [ 110 ] and miR-4712 [ 109 ] have been described as “oncomiRs” across multiple mammalian cell types, which is consistent with their role in RGCs. In addition, underexpressed miRNAs in RGCs such as miR-34 [ 124 ], miR-126 [ 72 ] and miR-196b [ 125 ] act as tumor suppressors.…”

Section: A Brief Overview On Mirnas and Their Regulated Targets In Rgcsmentioning

confidence: 99%

“…Methylation-associated silencing of miR-126 and its host gene EGFL7 has been demonstrated in pleural mesothelioma [ 168 ], suggesting an association between EGFL7 and miR-126. Due to the similarities between granulosa cell tumors and those of mesothelial lineage, Tu et al [ 72 ] showed that miR-126 constrains the tumorigenesis of granulosa cell tumors via directly targeting EGFL7 and suppressing the phosphatidylinositol 3-kinase/ATK (PI3K/AKT) pathway. This suggests that miR-126 may be utilized as a prognostic marker or a therapeutic target for granulosa cell tumor treatment.…”

Section: A Brief Overview On Mirnas and Their Regulated Targets In Rgcsmentioning

confidence: 99%

See 1 more Smart Citation

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Fiore

Suleiman

Pentimalli

et al. 2021

IJMS

View full text Add to dashboard Cite

Gynecological cancers pose an important public health issue, with a high incidence among women of all ages. Gynecological cancers such as malignant germ-cell tumors, sex-cord-stromal tumors, uterine sarcomas and carcinosarcomas, gestational trophoblastic neoplasia, vulvar carcinoma and melanoma of the female genital tract, are defined as rare with an annual incidence of <6 per 100,000 women. Rare gynecological cancers (RGCs) are associated with poor prognosis, and given the low incidence of each entity, there is the risk of delayed diagnosis due to clinical inexperience and limited therapeutic options. There has been a growing interest in the field of microRNAs (miRNAs), a class of small non-coding RNAs of ∼22 nucleotides in length, because of their potential to regulate diverse biological processes. miRNAs usually induce mRNA degradation and translational repression by interacting with the 3′ untranslated region (3′-UTR) of target mRNAs, as well as other regions and gene promoters, as well as activating translation or regulating transcription under certain conditions. Recent research has revealed the enormous promise of miRNAs for improving the diagnosis, therapy and prognosis of all major gynecological cancers. However, to date, only a few studies have been performed on RGCs. In this review, we summarize the data currently available regarding RGCs.

show abstract

microRNA-126 Is a Tumor Suppressor of Granulosa Cell Tumor Mediated by Its Host Gene EGFL7

Cited by 9 publications

References 42 publications

Regulation of miR-126 and miR-122 Expression and Response of Imatinib Treatment on Its Expression in Chronic Myeloid Leukemia Patients

Regulation of miR-126 and miR-122 Expression and Response of Imatinib Treatment on Its Expression in Chronic Myeloid Leukemia Patients

MicroRNA expression integrated analysis and identification of novel biomarkers in small cell lung cancer: a meta-analysis

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Contact Info

Product

Resources

About